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Tli is t l .resis addresses plccl inical and cl inicrr l  aspects of Iren,drugs, drug resislatrce atrd
sensit i \ , i ty ir .r  lung cancel r.r , i th empirasis on the role of apoptosis. Both irrtr insic arld acquilcd
rcsistance to chentotherapeLrt ic drLrgs arc a major obstacle in the treatmcut o1'non-sural l  cel l
lung cancer (ntSCLC). Apart Ír"onr classical drug resistancc mechanisms also fai lure of turtror '
cel ls to undergo progral l ' lmed cel l  death (apoptosis) is considerecl of major impor.tancc fbr '
resistance to chemotherapy or radiotherapy in tumors. Several proteins such as p53, I tb, p21,
c-myc, Bc1-2, Bax, F-as and Fas-l igand are involved in the apoptotic process. Distnrbance of
the nonlal Íunctioning and expression ofthese protcins can aiÏèct the capacity oftumor ccl ls
to undergo apoptosis, altcr treatnlent by racliation or chetnothe't'ap1 ' 
'.
Chapter 2 reviews studies regarding the prognostic irnpact of these apopt()I ic l)r 'oteinb rr
N-.SCLC patients. Furthemrorc this cliapter addresses targets for nen' drug treatntents
ruri 'olving apoptotic processes. Attention is paid to dif ïerent apoplot ic path\\ 'ays induced b1'
natural ly occuning death receptor i igands (such as TNF, F-as-l igand, ' f  RAIL) or induccd b1'
drugs that affect the EGF rcceptor or its dounstream route. Insight in the proteins tLrat
dctenl ine sensit ivi ty for chenrotherapeutic drugs may providc new tarsets for cancer
treatrnent, u'hich may lielp to, at least par1ly, overconte drug resistaucc in NSCI-Cl.
Apart of lhe apoptosis pathway in tunror cells, differcnces in cell morphology and
expressiou of apoptosis related proteins induced by radiation and/or chemotherap\,, r,r,ere
investigatccl in a rat model. In thjs rat nrodcl two tumols werc xcnograÍted for companson of
treatment ct-fccts in cisplat in sensit i \re iurd resist iurt l runran SCI-Cl tumors. ' lhis is describcd in
chapter 3. l 'he cisplat in scnsit ive lruman SCLC cel l  l ine CLC4 and i ts crsplat in resrstant
subl ine GI-C:I-CDDP rverc each ir.r . lected subcutaneously in a cl i f fercnt l i ind l imb oÍ-the rat.
Aftcr at least trvo rvecks oí ' lunror grolvth, t l .re anirnals rcccivcd radiat ion, carboplal in,
conrbincd treatnrent, or no tÍeatment. AÍier therapy, rrorphologic changes in cel l  size and cel i
size hetcrogeneity rvcrc r lorc pronoulrced in GLC:I than irr Gt.Cl-( 'DDP tunrors.
Neverthelcss, the morphologic changes in GI-C4-CC'DP trLmors fol lox' ing treatmcr)1, indicatc
that carboplat in plus radiotherapy treatment nray also be eÍ ' fect ive in plat inunr rcsistrrt  tunror
cel ls, hl GLC.4 tumors, an increase ir.r  p21 rvas observed aíter radial ion. Theoretical ly this
nright íaci l i tatc apoptosis. GLC4-CDDP shoived a consistcntly negative p21 status aftcl  anv
treatment. I-ogetl .rer with the incrcase in number of Bcl-2 posit ive cel ls al1er conrbined
treatrnent his might protect these tumor ccl ls for apoptosis, possibly as a part oí ' thcir
nrechanisnr fcrr plat inum rcsistance.
Chapter 4 describes the prognostic inrpl icat ion of exprcssit ln oí apoptosis-relatet l
proleins in tumor biopsies, obtained at diagnosis liorn 95 patients ri,ith locally aclvancecl
(stage II la,,b) NSCLC. The patients were treated rvit l ' r  ci ther radiat iorr alone or radiat ion
conrbined rvith continuous intravenous carboplat in infusion in a randornizecl study'.
Expression ofp53, Rb, p2l,  c-nryc, Bcl-2, Bax, Fas and Iras-l igand rvas asscssed in their
tur.nors by immunohistochemistr l , .  Thc results shon, that Bcl-2 crpressiorr prechcts lol better
overal l  sun' ival,  u4ri le p53, Bcl-2, and FasL cxpression predict lbr longer t inrc to plogressiorr.
Cl inical relevance of thesc Í indings is st i l l  l inr i tcd, t lue to small  impact ol-thcsc Íàctors on thc:
shorl sun' ival t inre in rnost patients with aclvanccd iseasc stage and because currcrrt ly no
alternal ive tai lorcd lreatment is avai lable.
Chapter 5 describcs a study in local ly advanced NSCI-Cl patients conrplr irrg trcatnrr-nt
. ,vi th rat l iothcrapy alone or radiotherapy combrncd with continuous carboplat in infusion.
Addit ion of carboplatrn to radiat ion hardly gave henratologic toxicity and aclcled nri ld
Chapter_10
nonhematologic toxicity to radiation toxicity. llowever, despite preclinical Íindírrgs, adrlition
of continuously aclministerecl low-dose carboplat in as radiosensit izer did not inrprove local
tumor corl troi or overal l  sulvival in local ly unreseclable non-small-cel l  lung cancer paticnts.
The second part oft tr is thesis addresses the eÍ ' fect of ne*, cytotoxic agents. In chaptcr ír
results of a pirase I strxly are described. The airr-r of this stLrdy was to assess feasibility,
phamracokinetics and toxicity of rnethoxyrnorpholino doxorubicin (MMRDX) administered
as a 3 irours intravenous infusion once every 4 weeks. Morpholinyl anthracyclines, such as
MMRDX, have shou,n activi t l 'on rnult idmg resistant unloÍs in precl inical nrodels t .  A phesr-
i  study and a phase II  stui ly rvi th bolus injeotion oiMlVÍRDX, shorved myelosuppressiou
(neutiopenia and trombocytopenia) as dose l inr i t ing toxicity 'o. Othcr anthracl,cl ines horved
less toxicit l ,  when administerei l  as prolonged infusion than as bolus infusion. ' f  herelbre,
I,{MRDX u'as adrninistered as a prolonged infusion in this study. Hor.vever, in the prolonged
ir.rfusion schedule MMRDX shorved increased nryelosr, ippression compared 1o bolus infusion,
which could not be explai i .red by phamiacokinetics parameters" Non-haematologicai toxici ty
was simiiar for prolonged and bolus infusion.
Until nor.v, one of thc most irnportant dmgs in the trcatrnent of lung cancer, is cisplatin,
although cisplatin has considerable side effects, and tumor resistance rriay linrit its elhcacy.
F'or t l t is reason, several new plat inum componnds have been syrthesized in order to reducc
side eflecis and,/or to overcome platinr.rm resistance. One of the syrtl'resized platinunr drugs
that showed prornising results in the precl inical phase is JM216. Both laboratory and ci inical
studies r l , i th JM2ió are described in the last chapters of this thesis. [n chapter 7 the anti- tunror '
poieÍrcy of JN,421ó and i ts major metaboli te JM1i8 is studied in a panel oÍ-hrman tunror cel l
l ines u, i th di l ferent sensi i i r , , i t ies for cisplat in, including cisplat in sensit ive, intr insrc lcsistant
and acquircd resistant cel l  l ines. Glutathione levels were measured to study the role of the
glutathione detoxilyiltg systeni on DNA-platination by these drugs. This study shou.ed thal
JM216 and especial ly i ts rnajor netaboli te JMl l8 is capable of parl ial iy circunrventirg
intr insic and acquired cisplat in resislance. JM118 was the lar nrost potent drug at cquimolar
base. DNA-plat ination by JM2l6 u,as cornparable to DNAllat ination b.v cisplat in. Drug-
induced cy'totoxicity correlatei ' l  negatively u i th glutathione levcls lor JM21ó and CDDP in the
tested cel l  l ines rvithout induced cisplat in rcsistance. No correlat ions \vere found betr '" 'een
drug-induced cytotoxicity ancl ini t ial  plat inurr-DNA addr"rct [eve]s or p5-j  status; ini t ial
plat inurrt-DNA adduct levels and glutathione levels or p-53 slatus; glutathionc lcvels and p53
status. I t  can be concluded that cisplat in ïesistant cel l  l ines shorveci relat ive high DNA-
plat ination conrpared to sensit ive cel l  l ines suggesting a resistance nrechanisnr bascd on
iolerance or increased DNA repair,  rathcr thau decreased init ial  plat inurl-DNA adduct
fom.ration.
Chapter 8 describes a pllasc II study determining tumor eI'Ílcacy and side cÍfects of tlic
o r a l  p l a t i n u r n d r u g J M 2 l 6 i n S C L C p a t i e n t s . J ' u m o r r e s p o n s e r a t e $ , a s  l 0 o L r t o f 2 T p a t i e n t s
(37%,95% CI 19-58%). No completc responses were obsen'ecl.  N4ost ir l rportul toxici t ics
rvere grade II I  and IV hematological toxici t ics, according to the common iorici ty cr- i tel ia.
This study showed that single agcnt JM216 is effect ive in a part of SCLC patients.
Since one of the major side cffects oÍ 'cisplat in is nephrotoxicity ' 'n, the renal cl ïects of JN42 1ó
were investigated in a study described in chapter 9. Prior to treatment, after the first
chemotherapy cycle and after the end of treatment, renal function r.vas assessed by 1r'l-so.liun.r
thalamate and ' ' ' I -hippuratc cleaÍances to detennine acute and cumulative changes in
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glomerular damage were assessed by urinary excretion of B2-microglobulin, lactic
dehydrogenase, aikaline phosphatase, gamma-glutamyltransferase nd albumin. In this study
no renal toxicity of JM216 was observed. So, although 1M216 is a platinum analogue with
some activity in SCLC patients as single agent and a relatively mild toxicity profile, the drug
has not been further developed due to adverse effects when combined with other oral drues.
such etoposide.
Future perspectives
Recently, Schiller et al e;10 showed in a randomized study in NSCLC patients that there was
no clear difference between a reference treatment regimen of cisplatin and paclitaxel versus
three experimental regimens. The response rate for all 1,155 eligible patients was 19% with a
median survival of 7.9 months. These results have emphasized the need to explore completeiy
new treatment options for NSCLC patients. Further investigation of the role of proteins
involved in apoptosis may provide important insight in the effect of the "classical" treatment
forms, chemotherapy and radiotherapy and will also provide insight in new targets for future
treatment options. The use of RNA expression micro-arrays can possibly help to provide
better information on up- or dolvnregulation of these proteins. Clinical appiication of these
aÍïays may lead to a more speciÍic drug approach. Furthermore, data will become available
from gene therapy studies in which e.g. wild-type p53 is delivered to tumor cells 1r-14.
Blocking of proliferation-inducing receptors and pathways of the EGF-family by e.g. tyrosine
kinase inhibitors enhances chemosensitivity of tumor cells l5-17. For instance, triais with
ZDl839, a kinase inhibitor of the EGFl-pathway, showed about 15% response rates as
second-line or third-line treatment in NSCLC 15-ri.
Also the ligand TRAIL binding to TRAIL death-receptors located at the cell membrane can
result in apoptosis in tumor celi lines along a route different from the route induced by
chemotherapy '0. The use of recombinant human TRAIL potentiates the effect of chemo- and
radiotherapyin preclinical moclels and may be of interest for clinical use. Hopefuliy,
combination of these new approaches with conventional chemotherapy and radiotherapy may
yield better results in future treatment of lung cancer.
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